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Why peptides/peptide-mimetics?
• Biocompatible
• Biodegradable
• Antimicrobial action
• Versatility 
• Reduced synthesis times
Peptide-mimetic hydrogels
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Synthesised sequence  conjugate drug  hydrogel formation  sustained release 
Therapeutic application
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Soluble peptide-mimetic-antiretroviral conjugate 
administered subcutaneously each month.
Phosphatase enzymes within the tissue cleave the 
phosphate group from the sequence backbone to 
afford a protease resistant hydrogel.
Sustained release of conjugated
antiretroviral drug from stable peptide-mimetic 
hydrogel via hydrolysis of drug-ester linkage.
Subcutaneous 
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Drug release
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Covalent attachment of AZT
Physical AZT encapsulation
Physical encapsulation, drug 
release via diffusion through 
hydrogel matrix
Covalent conjugation, drug release 
via hydrolysis of ester bond 
followed by diffusion through 
hydrogel matrix
H2O
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